Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling…
IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on…
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420…
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million…
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million…
The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…
The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…
The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…
November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq:…
The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society…